Skip to main content

Marizyme

  • About
      • Back
      • Overview
      • Executive Management
      • Board of Directors
      • Corporate Governance
  • Products
      • Back
      • Overview
      • DuraGraft®
      • Krillase®
      • MATLOC™ Platform
  • Clinical
      • Back
      • Publications
      • DuraGraft Publications
      • MATLOC Publications
  • Investors
  • Contact
      • Back
      • Contact Us
  • Sign Up
  • Language
      • Back
      • GER
adobe stock 229690447 preview

Products
DuraGraft®

  • Overview
  • DuraGraft®
  • Krillase®
  • MATLOC™ Platform

What is DuraGraft®?

Group 4531

DuraGraft is the first and only approved solution for the preservation of vascular conduits to reduce complications of vein graft disease and vein graft failure. An estimated 49% of patients going through CABG procedures experience at least one vein graft failure in the first year following surgery while an individual vein graft has a 30% chance of failure within the first year.

This single-use intraoperative vascular graft treatment improves clinical outcomes by preventing ischemic injury and subsequent reperfusion injury thereby maintaining endothelial function, thereby reducing the incidence and complications of graft failure.

DuraGraft is not yet available in the United States.

Product Description

DuraGraft Vascular Conduit Solution is intended for use during the harvesting and grafting interval of vascular surgery to maintain structural and functional integrity of vascular conduits.

How does DuraGraft® compare to the Current Standard of Care?

DuraGraft is Emerging as the New Standard of Care for Coronary Artery Bypass Surgery Globally

Limitations of the current standard of care solutions

Saline, blood and buffered solutions are widely used but are not indicated for use and do not protect against Ischemic Injury and do not protect against subsequent vein graft disease and graft failure

 

Clinical Needs

 

noun failure 882793 49%
patient level graft failure
noun debt 4815103 Economic Burden
on Healthcare System
noun surgery 1524821 Vein Graft Failure
is associated with poor clinical outcomes post-CABG

DuraGraft® Market Size

 

icondura1

$16.1B

Was the global coronary artery bypass graft procedures market size in 2018 & It is anticipated to expand at a CAGR of 1.7% from 2019 to 2025.*

icondura2

Up to ~1,000,000

Number of Heart bypass (CABG) procedures estimated to be performed worldwide every year.

icondura2

Up to 350,000

CABG surgeries performed annually in the US

*There is no guarantee that the market will continue to grow at this rate or that such a growth rate will be experienced by Marizyme.

 

imgfooter

Marizyme, Inc. is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical technologies that improve patient health outcomes.

 

Investors

  • Back
  • Stock Info
  • SEC Filings
  • Corporate Governance

Contact

  • Back
  • Contact Us
  • Sign Up
 

Get In Touch 

noun map 223137 555 Heritage Drive, Ste. 205,
Jupiter, FL 33458
noun phone 4637987 (561) 935-9955
noun email 3083073 info@marizyme.com 
Marizyme
© Copyright - 2023 Marizyme Inc. | All Rights Reserved | Website by Sandman Media Inc